All In Biotech

Drug Trial Radar · NCT00433420

Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer

A Phase III Randomized Study of EC Followed by Paclitaxel Versus FEC Followed by Paclitaxel, All Given Either Every 3 Weeks or 2 Weeks Supported by Pegfilgrastim, for Node Positive Breast Cancer Patients

Last checked: Nov 20, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 2,000 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

2,000

Planned (sponsor's estimate)

Start

Apr 2003

Primary completion

May 2006

Study completion Dec 2027

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Gruppo Italiano Mammella (GIM)
First posted
Feb 12, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, paclitaxel, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Colony-stimulating factors, such as pegfilgrastim, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy. Giving combination chemotherapy and pegfilgrastim after surgery may kill any tumor cells that remain after surgery. It is not yet known whether combination chemotherapy is more effective with or without fluorouracil and/or pegfilgrastim in treating breast cancer. PURPOSE: This randomized phase III trial is studying combination chemotherapy to compare how well it works when given with or without fluorouracil and/or pegfilgrastim in treating women with node-positive breast cancer.

Conditions

  • Breast Cancer

Interventions

  • pegfilgrastimBiological

  • cyclophosphamideDrug

  • epirubicin hydrochlorideDrug

  • fluorouracilDrug

  • paclitaxelDrug

  • adjuvant therapyProcedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free survival

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.